We have shown that the expression of CD86 was elevated in ibrutinib resistant samples, suggesting that these CLL cells are re-activated by escaping the inhibitory effect of ibrutinib. The gene discussed is CD86; the disease is B-cell chronic lymphocytic leukemia.